版本:
中国

BRIEF-Flamel Technologies reaches agreement with FDA on protocol for phase III pivotal trial of FT218

Oct 6 Flamel Technologies SA :

* Flamel Technologies reaches agreement with fda on protocol for phase III pivotal trial of FT218

* Phase III trial commenced patient enrollment in canada, with sites in Europe and U.S. to be initiated near-term

* Says agreement was reached through special protocol assessment process Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐